Nona Biosciences Enters Exclusive License Agreement With Pfizer For MSLN-Targeted Antibody-Drug Conjugate, HBM9033; To Receive Total Of Up To $53M Plus Up To $1.05B In Milestones
Portfolio Pulse from Benzinga Newsdesk
Nona Biosciences has entered into an exclusive license agreement with Pfizer for the MSLN-targeted antibody-drug conjugate, HBM9033. Nona will receive up to $53 million in upfront and near-term payments, and could receive up to $1.05 billion in milestones, plus royalties. This partnership with Pfizer expands Nona's global collaborations and underscores its commitment to technology innovation in therapeutics development.
December 14, 2023 | 11:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Pfizer has entered into a licensing agreement with Nona Biosciences for HBM9033, which could lead to significant financial commitments totaling up to $1.05 billion in milestones plus royalties, in addition to $53 million in upfront and near-term payments.
The agreement with Nona Biosciences represents a strategic investment by Pfizer into a potentially lucrative oncology drug, HBM9033. The financial commitment suggests a strong belief in the drug's prospects, which could positively influence Pfizer's stock in the short term as investors may view this as a move to strengthen its pipeline in a high-value therapeutic area.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80